CD274 and lung carcinoma: Site-specific heterogeneity in PD-L1 expression mirrors evidence from lung cancer [17] and combines with analytical heterogeneity as an important factor underscoring the suboptimal performance of PD-L1 in predicting immunotherapy outcomes in HCC.